Edoxaban In Prevention Of Stroke In Patients With Atrial Fibrillation

Atrial fibrillation is the most common arrhythmia,Patients with AF are susceptible to developing cardioembolic stroke.warfarin has traditionally been used for stroke prevention.Although effective,warfarin use is fraught with multiple concerns,such as a narrow therapeutic window,drug–drug and drug–food interac?tions,frquence need of INR(international normalized ratio,INR)minitoring.Novel oral anticoagulant agents(Direct thrombin inhibitor dabigatran and factor Xa inhibitors like rivaroxaban and apixaban)have recently become available as viable alternatives for warfarin therapy.Edoxaban is the latest oral direct factor Xa inhibitor studied in the largest novel oral antico?agulant trial so far: ENGAGE AF-TIMI 48.edoxaban was found to be noninferior to dose-adjusted warfarin in reducing the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation,with a lower incidence of bleeding complications and cardiovascular deaths.This article reviews the clinical trials and the progress of clinical application of edoxaban.